Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s sarcoma

Bibliography

• KAPOSI M: Idiopathisches multiples pigmentsarkom der haut. Arch. Dermatol Syphilol (1872) 4:265–273.
   Google Scholar
• SLAVING, CAMERON HM, SINGH H: Kaposi's sarcoma in mainland Tanzania: a report of 117 cases. Br. Cancer (1969) 23:349–357.
   Web of Science ®Google Scholar
• TAYLOR IF, SMITH PG, BULL D, PIKE MC: Kaposi's sarcoma in Uganda: geographic and ethnic distribution. Br. Cancer (1972) 26:483–497.
   Web of Science ®Google Scholar
• PENN I: Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation (1979) 27:8–11.
   PubMed Web of Science ®Google Scholar
• TRATTNER A, HODAK E, DAVID M, SANDBANK M: The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer (1993) 72:1779–1783.
   PubMed Web of Science ®Google Scholar
• BERAL V, PETERMAN TA, BERKELMAN RL, JAFFE HW: Risk of Kaposis's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet (1990) 335:123–128.
   PubMed Web of Science ®Google Scholar
• BIGGAR RI, RABKIN CS: The epidemiology of AIDS-related neoplasms. Hematol Omni Clin. North Am. (1996)10:997–1010.
   PubMed Web of Science ®Google Scholar
• •Careful analysis of the impact of malignancies in people with AIDS.
   Google Scholar
• BRODT HR, KAMPS BS, KNUPP B, STASZEWSKI S, HELM EB: Changing incidence of AIDS-defining illness in the era of antiretroviral therapy. AIDS (1997) 11:1731–1738.
   PubMed Web of Science ®Google Scholar
• NASTI G, VACCHER E, ERRANTE D,TIRELLI U: Malignant tumors and AIDS. Biomed. Pharmacother. (1997) 51:243–251.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL COLLABORATION ON HIV AND CANCER: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. Natl. Cancer Inst. (2000) 92:1823-1830. Important overview that highlights the dramatic impact of HAART on HIV-related cancers.
   Google Scholar
• GILL PS, AKIL B, COLLETI P et al: Pulmonary Kaposi's sarcoma. Clinical findings and results of therapy. Am. j Med. (1989) 87:57–61.
   Google Scholar
• KAPLAN LD, HOPEWELL PC, JAFFE H et al.: Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J. Acquic Immune Defic. Syndr: (1988) 1:23–30.
   PubMed Web of Science ®Google Scholar
• REGEZI JA, MacPHAIL LA, DANIELS TE, DESOUZA YG, GREENSPAN JS, GREENSPAN D: Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am. Pathol (1993) 143:240–249.
   Google Scholar
• SCHULZ TF, BOSHOFF CH, WEISS RA: HIV infection and neoplasia. Lancet (1996) 348:587–591.
   PubMed Web of Science ®Google Scholar
• ENSOLI B, GENDELMAN R, MARKHAM P et al.: Synergy between basic fibroblastic growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature (1994) 371:674–680.
   PubMed Web of Science ®Google Scholar
• AOKI Y, JAFFE ES, CHANG Y et al: Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 93:4034–4043.
   PubMed Web of Science ®Google Scholar
• MENSRI EA: Inflammatory reactivation and angiogenity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood (1999) 93:4031–4033.
   PubMed Web of Science ®Google Scholar
• ••Elegant discussion on the relationshipbetween HHV-8 and the inflammatory angiogenic milieu necessary for the growth of KS.
   Google Scholar
• HOLKOVA B, TAKESHITA K, CHENG DM et al.: Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. j. Omni (2001) 19:3848–3851.
   Google Scholar
• SWITH PS: The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Hematol Omni Clin. North kn. (1996) 10:169–180.
   Web of Science ®Google Scholar
• GRESSEN EL, ROSENSTOCK JG, XIE Y, CORN BW: Palliative treatment of epidemic Kaposi sarcoma of the feet. Am. Gin. Omni (1999) 22:286–290.
   PubMed Web of Science ®Google Scholar
• LOONEY DJ, WIKTHE W, FEIGAL E et al.: Relationship of HHV-8 peripheral blood mononuclear cell burden to immunodeficiency, opportunistic infections, response to therapy and stage of Kaposi's sarcoma. First National AIDS Malignancy Conference, Bethesda, MD. Acquir. Immune Defic. Syndr. (1997) 14:A35.
   Web of Science ®Google Scholar
• TAPPERO JW, BERGER TG, KAPLAN LD, VOLBERDING PA, KAHN JO: Cryotherapy for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS): a Phase II trial. I Acquir. Immune Defic. Syndr. (1991) 4:839–846.
   PubMed Web of Science ®Google Scholar
• SWIFT PS : Radiation therapy in the management of HIV-realted KS. Hematol Omni Clin. North kn. (1996) 10:1069–1080.
   PubMed Web of Science ®Google Scholar
• STELZER KJ, GRIFFIN TW: A randomised prospective trial of radiation therapy for AIDS associated Kaposi's sarcoma. Int. Radiat. Oncol . (1993) 27:1057–1061.
   Web of Science ®Google Scholar
• EPSTEIN JB, LOZADA-NUR F, MCLEOD WA, SPINELLI J: Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and 509 report of the efficacy of intralesional vinblastine. Cancer (1989) 64:2424–2430.
   Google Scholar
• BOUDREAUX AA, SMITH LL, COSBY CD, BASON MM, TAPPERO JVV, BERGER TG: Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection.' Am. Acad. Dermatol (1993) 28:61–65.
   Google Scholar
• WALMSLEY S, NORTHFELT DW, MELOSKY B, CONANT M, FRIEDMAN-KIEN AE, WAGNER B: Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel." Acquit: Immune Defic. Syndr. (1999) 22:235–246.
   Google Scholar
• •Phase III clinical study that provides evidence of the efficacy of alitretinoin as a novel agent for local KS treatment.
   Google Scholar
• BODSWORTH NJ, BLOCH M, BOWER M, DONNEL D, YOCUM R: Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am. J. Clin. DermatoL (2001) 2:77–87.
   PubMedGoogle Scholar
• SCOLARO MJ, GUNNILL LB, POPE LE, KHALIL MH, KATZ DH, BERG JE: The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIVType-1-infected patients: a pilot clinical study. AIDS Res. Hum. Retroviruses (2001) 17:35–43.
   PubMed Web of Science ®Google Scholar
• •Pilot study providing impetus for further investigation of docosanol.
   Google Scholar
• McCARTY MF, BIELENBERG D, DONAWHO C, BUCANA CD, FIDLER II: Evidence for the casual role of endogenous interferon-a/13 in the regulation of angiogenesis, tumorigenicity, and metastais of cutaneous neoplasms. Clin. Exp. Metastasis (2002) 19:609–615.
   PubMed Web of Science ®Google Scholar
• HO DD, HARTSHORN KL, ROTA TR et al.: Recombinant human interferon-a suppresses HTLV-III replication in vitro. Lancet (1985) 1:602–604.
   PubMed Web of Science ®Google Scholar
• MONINI P, CARLINI F, STURZL M et al.: a-Interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells." Vico/. (1999) 73:4029–4041.
   Google Scholar
• KROWN SE: Interferon and other biological agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin. North Am. (1991) 5:311–322.
   PubMed Web of Science ®Google Scholar
• VOLBERDING PA, MITSUYASU RT, GOLANDO JP et al.: Treatment of Kaposi's sarcoma with interferon a-2b (Intron). Cancer (1987) 59:620–625.
   PubMedGoogle Scholar
• MAUSS S, JABLONOWSKI H: Efficacy, safety, and tolerance of low-dose, long-term interferon a-2b and zidovudine in patients with AIDS-related Kaposi's sarcoma. Acquir. Immune Defic. Syndr. (1995) 10:157–162.
   Web of Science ®Google Scholar
• FISCHL MA: Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma. Am. J. Med. (1991) 90:2S.
   PubMed Web of Science ®Google Scholar
• KROWN SE, GOLD JWM, NIEDZWIECKI D et al.: Interferon-a with zidovudine: safety, tolerance, and clinical and virological effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. (1990) 112:812–821.
   PubMed Web of Science ®Google Scholar
• SHEPHERED FA, BEAULIEU R, GELMON K et al.: Prospective randomized trial of two dose levels of interferon a with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials network Study. J. Clin. OncoL (1998) 16:1736–1742.
   PubMed Web of Science ®Google Scholar
• KROWN SE, PING LI, VON ROENN JHet al.: Efficacy of low dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized Phase II AIDS Clinical Trials Group Study. I Interferon Cytokine Res. (2002) 22:295–303.
   Google Scholar
• LAUBENSTEIN LJ, KRIGEL RL, ODAJNYK CM et al.: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastin. I Clin. Oncol (1984) 2:1115–1120.
   PubMed Web of Science ®Google Scholar
• VOLBERDING PA, ABRAMS D, CONANT M et al.: Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann. Intern. Med. (1985) 103:335–338.
   PubMed Web of Science ®Google Scholar
• MINTZER D, REAL FX, JOVINO L et al.: Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with acquired deficiency syndrome. Ann Inter Med(1985) 103:200–202.
   Web of Science ®Google Scholar
• CHACHOUA A, GREEN M, LAUBESTEIN L et al.: Phase II study of oral idarubicin in patients with AIDS associated Kaposi's sarcoma. Cancer Treat. Rev (1987) 71:775–776.
   Google Scholar
• GILL PS, RARICK M, BERSTEIN-SINGER M: Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am. Clin. Oncol (1990) 13:315–319.
   PubMed Web of Science ®Google Scholar
• CAUMES E, GUERMONPREZ G, KATLAMA C et al: AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin. AIDS (1992) 6:1483–1487.
   PubMed Web of Science ®Google Scholar
• FISCHL MA, KROWN SE, O'BOYLE K et al.: Weekly doxorubicin in the treatment of patients with AIDS related Kaposi's sarcoma. Acquit: Immune Defic. Synth: (1993) 6:259–264.
   PubMed Web of Science ®Google Scholar
• REMICK SC, REDDY M, HERMAN D et al.: Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma. J. Clin. Oncol (1994) 12:1130–1136.
   PubMed Web of Science ®Google Scholar
• SCHWARTSMANN G, SPRINZ E, KROMFELD M et al: Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposcsarcoma with no prior exposure to cytotoxic therapy. Clin. Oncol (1997) 15:2118–2124.
   Web of Science ®Google Scholar
• GILL PS, RARICK M, McCURCHAN JA et al.: Systemic treatment of AIDS-related Kaposi's sarcoma. Results of a randomised trial. Am. Med. (1991) 90:427–433.
   PubMed Web of Science ®Google Scholar
• NORTHFELT DW, DEBUZE B, MILLER B et al: Randomized comparative trial of Doxil versus Adriamicin, bleomicyn, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma. Blood (1995) 86:382a
   Web of Science ®Google Scholar
• STEWART JSW, JABLONOWSKI H, GOEBEL FD et al: A randomised comparative trial of Doxil versus bleomycin and vincristine (BV) in the treatment of AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol (1997) 16:55a
   Web of Science ®Google Scholar
• SHARPE M, EASTHOPE SE, KEATING GM, LAMB HM: Polythylene glycol-liposomal doxorubicin. Drug (2002) 62:2089–2126.
   PubMed Web of Science ®Google Scholar
• MASOOD R, HUSAIN SR, RAHMAN A et al.: Potentiation of cytotoxic of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome encapsulated doxorubicin. AIDS Res. Hum. Retrovir. (1993) 8:741–745.
   Web of Science ®Google Scholar
• NORTHFELT DW, MARTIN FJ, WORKING P et al.: Pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. J. Pharmacol. (1996) 366:55–63.
   Google Scholar
• Expert Op/n. lnvestig. Drugs (2004) 13(5)
   Google Scholar
• BERRY G, BILLINGHAM M, ALDERMAN E et al.: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. OncoL (1998) 9:711–716.
   PubMed Web of Science ®Google Scholar
• GILL PS, WERNZ J, SCADDEN DT et al.: Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi's sarcoma. J. Clin. Oncol (1996) 14:2353–2364.
   PubMed Web of Science ®Google Scholar
• •Important Phase III trial confirming significant activity of liposomal daunorubicin leading to approval of the drug in the US.
   Google Scholar
• NORTHFELT DW, DEBUZE B, THOMMES JA et al.: Pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of randomized Phase III clinical trial." Clin. Oncol (1998) 16:2445–2451.
   Google Scholar
• •Phase III trial supporting the approval of doxorubicin in the US for the treatment of advanced KS.
   Google Scholar
• STEWART S, JABLONONSKI H, GOEBEL FD et al.: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. Clin. OncoL (1998) 16:683–691.
   Web of Science ®Google Scholar
• MYTSUYASU R, VON ROENN J, KROWN SE: Comparison study of liposomal doxorubicin alone or with bleomycin and vincristine for treatment of advanced AIDS-associated Kaposi's sarcoma: AIDS Clinical Trial Group (ACTG) Protocol 286. Proc. _Am. Soc. Clin. Oncol (1997) 16:55a
   Google Scholar
• HORWITZ SB, COHEN D, RAO S etal.:Taxol: mechanisms of action and resistance. [Natl. Cancer. Inst. Monogr. (1993) 15:55–62.
   Google Scholar
• KLAUBER N, PARANGI S, FLYNN E et al.: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. (1997) 57:81–86.
   PubMed Web of Science ®Google Scholar
• BELOTTI D, VERGANI V, DRUDIS T et al.: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. (1996) 2:1843–1849.
   PubMed Web of Science ®Google Scholar
• SGADARI C, TOSCHI E, PALLADINO C et al.: Mechanisms of paclitaxel activity in Kaposi's sarcoma. .1. Immunol (2000) 165:509–517.
   Google Scholar
• •A comprehensive review of the activity of paclitaxel in KS.
   Google Scholar
• VVELLES L, SAVILLE MW, LIETZAU Jetal.: Phase II trial with dose tritation of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma../. Clin. Oncol (1998) 16:1112–1121.
   Google Scholar
• GILL PS, TULPULE A, ESPINA BM et al:Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma../. Clin. Oncol (1999) 17: 1876-1883.
   Google Scholar
• TULPULE A, GROOPMAN J, SAVILLE MW et al.: Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi's sarcoma. Cancer (2002) 95:147–154.
   PubMed Web of Science ®Google Scholar
• •Large Phase II study confirming significant activity of paclitaxel even in patients who failed to respond to previous chemotherapy.
   Google Scholar
• STEBBING J, WILDFIRE A, PORTSMOUTH S et al.: Paxlitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann. Oncol (2003) 14:1660–1666.
   PubMed Web of Science ®Google Scholar
• PAREDES J, KAHN JO, TONG WP et a/.:Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a Phase I multicenter trial of the AIDS Clinical Trial Group. I Acquir: Immune Defic. Syndr: (1995) 9:138–144.
   Google Scholar
• SCOTT RE, KROWN E, TESTA MA, COOLEY TP, VON ROENN JH: Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group Clinical Study. .1. Clin. Oncol (2002) 20:3236–3241.
   PubMed Web of Science ®Google Scholar
• NASTI G, ERRANTE D, TALAMINI R etal.: Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a Phase II study. J. Clin. Oncol (2000) 18:1550–1557.
   Google Scholar
• LEBBE C, BLUM L, PELLET C etal.: Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS(1998) 12:F45–F49.
   Google Scholar
• •Although this is a small study it is the first to demonstrate the regression of KS during HAART.
   Google Scholar
• RIZZIERI DA, LIU J, IRA WEEK ST, MIRALLES GD: Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor. Lancet (1997) 349:775–776.
   PubMed Web of Science ®Google Scholar
• MURDACA G, CAMPELLI A, SETTI M, INDIVERI F, PUPPO F: Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS (2002) 16:304–305.
   PubMed Web of Science ®Google Scholar
• PORTSMOUTH S, STEBBING J, GILL J, MANDALIA S et al: A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS (2003) 11:F17–F22.
   Google Scholar
• BOWER M, FOX P, FIFE K et al.: Highlyactive anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS (1999) 13:2105–2111.
   PubMed Web of Science ®Google Scholar
• DUPIN N, RUBIN THE CERVENSV, GORIN I et al.: The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br. .1. Dermatol (1999) 140:875–881.
   Google Scholar
• CATTELAN AM, CALABRO ML, AVERSA SML etal.: Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer (1999) 35:1809–1815.
   Google Scholar
• DUPONT C, VASSEUR E, BEAUCHET A et al.: Long term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS (2000) 14:987–993.
   PubMed Web of Science ®Google Scholar
• GILL J, BOURBOULIA D, WILKINSON J et al.: Prospective study of the effects of antiretroviral therapy on Kaposi's sarcoma-associated herpesvirus infection in patients with and without Kaposi's sarcoma. J. Acquic Immune Defic. Syndr. (2002) 31:384–390.
   PubMed Web of Science ®Google Scholar
• CATTELAN AM, CALABRO ML, GASPERINI P et al.: Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biological correlates of clinical outcome. I Natl. Cancer Inst. Monogr. (2001) 28:44–49.
   PubMedGoogle Scholar
• •The study reports the highest remission rate of KS under HAART after a median follow up of 22 months.
   Google Scholar
• MONFARDINI S, CATTELAN AM, DE ROSSI A et al.: Highly effective antiretroviral therapy (HAART) and clinical outcome of AIDS-related Kaposi's sarcoma: a prospective study. Proc. Am. Soc. Clin. Oncol. (2003) 22:3295 (Abstract).
   Google Scholar
• KEDES DH, GANEM D: Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J. Clin. Invest. (1997) 99:2082–2086.
   PubMed Web of Science ®Google Scholar
• MEDVECZKY MM, HORVATH E, LUND T, MEDVECZKY PG: In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS (1997) 11:1327–1332.
   PubMed Web of Science ®Google Scholar
• ROBLES R, LUGO D, GEE L, JACOBSON MA: Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. j Acquic Immune Defic. Syndr. (1999) 20:34–38.
   Web of Science ®Google Scholar
• MOCROFT A, YOULE M, GAZZARD B et al.: Anti-herpesvirus treatment and the risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group../. Clin. Invest. (1997) 99:2082–2086.
   Google Scholar
• MARTIN DF, KUPPERMANN BD, WOLITZ RA, PALESTINE AG, LI H, ROBINSON CA: Oral ganciclovir for patients with cytomegalovirus retinitis treated with ganciclovir implant. Roche Ganciclovir Study Group. N Engl. I Med. (1999) 340:1063–1070.
   PubMed Web of Science ®Google Scholar
• GELSBY MJ, HOOVER DR, WENG S et al.: Use of antiherpes drugs and the risk of Kaposi's sarcoma: Data from the Multicenter AIDS Cohort Study. AIDS (1996) 10:1101–1105.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, GRIFFITH EC, SAGE J, JACKS T, LIU JO: Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1. Proc. Natl. Acad. Sci. USA (2000) 97:6427–6432.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ, VON ROENN JH, HOLDEN-WILTSE J et al: A Phase I dose escalation and pharmacokinetics study of TNP-470 in AIDS-related Kaposi's sarcoma. (ACTG-215).j Clin. Oncol. (1998) 16:1444-1449. so.KROWN SE: Treatment of Kaposi's sarcoma: the role of interferon and thalidomide. Carr: Opin. Oncol. (2001) 13:374-381. *4.An interesting commentary on the mechanisms by which IFN and thalidomide show their activity against KS.
   Google Scholar
• D'AMATO R, LOUGHNAN MS, FLYNN E et al: Thalidomide is an inhibitor of angiogenseis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• HASLETT PAJ, CORRAL LG, ALBERT M, KAPLAN G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. (1998) 187:1885–1892.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PAJ, MULLER GW ET AL: Differential Cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-a. Immunol. (1999) 163:380–396.
   Web of Science ®Google Scholar
• POLITI P, REBOREDO G, LOSSO M, VUJACICH C, SCHWARTSMANN G, LEWI D: Phase I trial of thalidomide in AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol. (1998) 17:41a
   Google Scholar
• LITTLE RF, KATHLEEN MW, PLUDA JM et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma. Clin. Oncol. (2000) 18:2593–2602.
   Web of Science ®Google Scholar
• SGADARI C, ANGIOLILLO AL, TOSATO G et al: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 87:3877–3882.
   PubMed Web of Science ®Google Scholar
• YAO L, SGADARI C, FURUKE K, BLOOM ET, TERUYA-FELDESTEIN J, TOSATO G: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1999) 93: 1612-1621.
   Google Scholar
• LITTLE RE PLUDA JM, WYVILL K, LIETZAU J, SHEARER G, TOSATO G: Interleukin 12 (IL-12) appears to be active in AIDS-associated Kaposi's sarcoma (KS): early results of a pilot study. 7th Conference on Retrovirus and Opportunistic Infections. San Francisco, USA (2000) (Abstract 5).
   Google Scholar
• IM862 (Investigator's brochure) 6th Edition. WA Kirland (Ed.), Cytran Inc., USA (1998).
   Google Scholar
• TULPULE A, SCADDEN DT, ESPINA BM et al: Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. Clin. Oncol. (2000) 18:716–723.
   Web of Science ®Google Scholar
• •Phase II clinical trial describing encouraging activity and low toxicities of IM-862 in KS therapy.
   Google Scholar
• NOY A, GILL P, SCADDEN D, LEE J et al.: Angiogenesis inhibitor IM862 is effective against AIDS-KS in a randomized, placebo controlled trial. 6th International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD, USA (2002).
   Google Scholar
• FONG TA, SHAWVER LK, SUN L et al.: 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flkl/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• MILES SA, ARASTEH K, GILL P et al.: A multicenter dose-escalating study of 5U5416 in AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol. (2000) 19:176a
   Google Scholar
• VIA LE, GORE-LANGTON RE, PLUDA JM: Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent 5U5416. Oncology (2000) 14:1321–1323.
   Google Scholar
• TOSCHI E, BARILLARI G, SGADARI C et al.: Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability M vitro by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Ma Biol. Med(1995) 1:65-68. los. FINGLETON B, MATRISAN LM: Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr. Opin. Oncol. (2001) 13:368–373.
   Google Scholar
• ••Well-written review on the role of MMPsas antiangiogenetic agents in KS.
   Google Scholar
• BARILLARI G, SGADARI C, FIORELLI V et al.: The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the a5131 and avI33 integrins by mobilizing sequestered basic fibroblast growth factor. Blood (1999) 94:663–672.
   PubMed Web of Science ®Google Scholar
• MEADE-TOLLIN LC, WAY D, WITTE MH: Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi's sarcoma cells. Acta Histochem. (1999) 101:305-316. los. CIANFROCCA M, COOLEY TP, LEE JY et al.: Matrix metallo-proteinases inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a Phase I AIDS Malignancy Consortium Study. I. Clin. Oncol (2002) 20:153-159. Phase I data providing impetus for further studies.
   Google Scholar
• CORBEIL J, RAPPAPORT E, RICHMAN DD, LOONEY DJ: Antiproliferative effect of retinoid compounds on Kaposis's sarcoma cells. Clin. Invest. (1994) 93:1981–1986.
   Google Scholar
• GUO WX, GILL PS, ANTAKLY T: Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res. (1995) 55:823–829.
   PubMed Web of Science ®Google Scholar
• GILL PS, ESPINA BM, MOUDGIL T et al.: All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma. Results of a pilot Phase II study. Leukemia (1995) 8:S26–S32.
   Web of Science ®Google Scholar
• SAIAG P, PAVLOVIC M, CLERICI T et al.: Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized Phase II trial. AIDS (1988) 12:2169–2176.
   Web of Science ®Google Scholar
• MILES SA, DEBUZE BJ, LEE JY et al.: Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS (2002) 16:421–429.
   PubMed Web of Science ®Google Scholar
• ABOULAFIA DM, NORRIS D, HENRY D et al: 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi's sarcoma: results of a Phase II multicenter trial. Arch. Dermatol (2003) 139:178–186.
   PubMed Web of Science ®Google Scholar
• LUNARDI-ISKANDAR Y, BRYANT JL, ZEMAN RA et al. : Tumorigenesis and metastasis of neoplastic kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature (1995) 375:64–69.
   PubMed Web of Science ®Google Scholar
• GILL PS, LUNARDI-ISKANDAR Y, LOUIE S et al.: The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl. J. Med. (1996) 335:1261–1269.
   PubMed Web of Science ®Google Scholar
• GILL PS, McLAUGHLIN T, ESPINA BM et al.: Phase I study of a preparation of human chorionic gonadotropin given subcutaneously to patients with AIDS-related Kaposi's sarcoma. Natl. Cancer Inst. (1997) 89:1797–1802.
   Google Scholar
• TAVIO M, NASTI G, SIMONELLI C et al.: Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma. Ear. I. Cancer (1998) 34:1643–1647.
   Web of Science ®Google Scholar
• KROWN SE : Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J. Oncol ( 2004) 22:399–402.
   Web of Science ®Google Scholar
• STEBBING J, GAZZARD B, PATTERSON S et al.: Antibody-targeted MHC complex-directed expansion of HIV-1 and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination. Blood( 2004) 103:1791-1795. Affiliation Anna Maria Cattelan MDtl, Marco Trevenzoli MD1 & Savina Maria Lucia Aversa MD2 -rAuthor for correspondence -r1 Department of Infectious Diseases, University of Padua, Via Giustiniani 2, 35128 Padova, Italy Tel: +39 049 821 3741; Fax: +39 049 8213768 E-mail: [email protected] or [email protected] 2 Oncology Division, General Hospital, University of Padua, Italy
   Google Scholar